PTGS2 and ovarian carcinoma: On ovarian cancer cell lines characterized for COX isoforms expression and activity, SC-560 showed in vitro antiproliferative effects similar to those of indomethacin and celecoxib (non-COX isoform selective and COX-2-selective, respectively), and only at doses 50–100 times greater than those achieved in in vivo systems [140].